bluebird bio Newsroom

Barclays Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $40

Futu NewsDec 31, 2024 20:32

Bluebird Bio Analyst Ratings

BenzingaDec 31, 2024 19:04

Barclays Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $40

Futu NewsDec 31, 2024 11:32

Wells Fargo Maintains Bluebird Bio(BLUE.US) With Hold Rating, Maintains Target Price $2

Futu NewsNov 19, 2024 20:32

Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), Bluebird Bio (BLUE) and AC Immune SA (ACIU)

TipRanksNov 19, 2024 15:38

B of A Securities Downgrades Bluebird Bio to Neutral, Lowers Price Target to $0.5

BenzingaNov 16, 2024 01:03

Bluebird Bio Is Maintained at Overweight by Barclays

Dow JonesNov 15, 2024 22:48

Bluebird Bio Analyst Ratings

BenzingaNov 15, 2024 22:38

A Quick Look at Today's Ratings for Bluebird Bio(BLUE.US), With a Forecast Between $0.5 to $2

Futu NewsNov 15, 2024 21:04

J.P. Morgan Maintains Bluebird Bio(BLUE.US) With Hold Rating

Futu NewsOct 10, 2024 19:31

Bluebird Bio's Restructuring Efforts and Financial Outlook: A Cautious Hold Rating

TipRanksSep 28, 2024 01:18

Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo

Dow JonesSep 26, 2024 00:46

Bluebird Bio Analyst Ratings

BenzingaSep 26, 2024 00:37

Wells Fargo Maintains Bluebird Bio(BLUE.US) With Hold Rating, Cuts Target Price to $2

Futu NewsSep 25, 2024 18:32

Maintaining Hold on Bluebird Bio: Balancing LYFGENIA's Promise Against Financial and Operational Hurdles

TipRanksSep 25, 2024 17:49

Barclays Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $4

Futu NewsSep 25, 2024 17:33

Analysts Are Bullish on Top Healthcare Stocks: Bluebird Bio (BLUE), Immunic (IMUX)

TipRanksSep 25, 2024 17:07

William Blair Maintains Bluebird Bio(BLUE.US) With Hold Rating

Futu NewsSep 24, 2024 23:32

William Blair Reaffirms Their Hold Rating on Bluebird Bio (BLUE)

TipRanksSep 24, 2024 23:28

Bluebird Bio Analyst Ratings

BenzingaSep 16, 2024 20:27